Goodwin Advises Delix Therapeutics on Its $100 Million Series C Financing

Professionals

Felipe M. HeiderichAlison LiouCatherine MagazuKingsley L. TaftGozde GuckayaJulia ShaverLibby SousaAnikó Bouley, ACP

The Life Sciences team advised Delix Therapeutics on its oversubscribed $100 million Series C financing. The round was led by Johnson & Johnson through its corporate venture capital organization, Johnson & Johnson Innovation — JJDC, Inc., and SV Health Investors’ Dementia Discovery Fund (DDF), with participation from existing investors, such as RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures, and Bail Capital, as well as the addition of several new investors, including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital, and YK Bioventures, among others. The financing provides Delix with additional capital to advance zalsupindole through Phase IIb Proof of Concept in recurrent Major Depressive Disorder while supporting continued development of the company’s broader neuroplastogen pipeline. This includes advancement of additional development candidates and expansion of the neurodegeneration program with demonstrated preclinical efficacy signals.

Delix Therapeutics is a clinical-stage neuroscience company focused on harnessing the power of novel neuroplasticity-promoting therapeutics to better treat patients struggling with difficult-to-treat neuropsychiatric and neurological disorders. The company’s compounds are easily manufactured small molecules capable of rapidly inducing structural and functional neural changes in targeted areas of the brain. Through its novel Neuroplastogen Platform, Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and rapidly advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that are intended to serve several unmet needs and enhance the psychiatric treatment paradigm for patients and providers.

The Goodwin team was led by Catherine Magazu, Libby Sousa, Julia Shaver, and Kingsley Taft and included Gozde Guckaya, Felipe Heiderich, Alison Liou, and Anikó Bouley.

For more information on the deal, please read the press release.

Goodwin Advises Delix Therapeutics on Its $100 Million Series C Financing

Related Content

Delaware Court of Chancery Holds That “Transaction-Specific Control” Has No Place in Delaware’s Safe Harbor Statute

Teva and Samsung Bioepis Enter Into Licensing Agreement to Commercialize Etanercept and Infliximab Biosimilars in the U.S.

Fresenius and WuXi Biologics Enter Development Agreement

Theriva Biologics Sells Antibiotic-Degrading Enzyme Portfolio to Biossil Labs

Adalvo Expands Biosimilars Portfolio Through Acquisition of Romiplostim Biosimilar Program from Enzene

FDA Approves Xbrane’s LUCAMZI™, a Biosimilar to LUCENTIS®

China’s Ministry of Commerce Proposes Sanctions on Foreign Companies for Infringement of Chinese Trade Secrets

FDA Signals a “Fit-for-Purpose” Era for Rare Disease Developers with Action to Follow

Tom Henry to Join Goodwin as Co-Leader of Real Estate Industry Group in New York

Goodwin Advises Indivior Pharmaceuticals on Merger With Supernus Pharmaceuticals

Goodwin Advises Rapport Therapeutics on Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement for an Aggregate of $380 Million

Goodwin Advises Amanat Acquisition Corp on Definitive Business Combination Agreement with Corxel US

Goodwin Advises Disc Medicine on $450 Million Upsized Public Offering

Best Law Firms in France Recognizes Goodwin Paris Across Practices

Goodwin Advises Hansoh on Collaboration Agreement With Roche for $400 Million Upfront and Up To $15 Billion in Milestone Payments

Goodwin Advises Syndicate of Existing Investors on Microbiotica's £36 Million Series C Financing

Life Sciences